Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, October 30, 2018-A new study takes a close look at the content and potential implications of the new Texas law HB 810, which aims to expand assess of experimental stem cell interventions outside the realm of clinical trials under FDA oversight. HB 810 represents a new level of deregulation after the Right To Try laws and presents concerns including ambiguity over what constitutes a chronic illness, reporting requirements, and safety concerns, as described in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Stem Cells and Development website through November 30, 2018.
In the article entitled "Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?" coauthors Bhavana Kunisetty and Kirstin Matthews, PhD, Rice University, Houston, TX describe HB 810 as the first step toward an expansion of the Right to Try laws. Those laws, in response to the FDA's prolonged approval process, allow terminally ill to request access to experimental drugs without FDA approval. HB 810 gives access to investigational stem cell treatments to patients with certain severe chronic diseases or terminal illnesses.
"This important article reaffirms our continuing commitment as a journal to discuss issues germane to the responsible advancement of regenerative medicine," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
###
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Media Contact
Kathryn Ryan
[email protected]
914-740-2250
@LiebertPub
http://www.liebertpub.com
Original Source
https://home.liebertpub.com/news/how-will-texas-law-hb-810-impact-stem-cell-based-intervention-clinics/2467 http://dx.doi.org/10.1089/scd.2018.0148
